Wells Fargo Initiates Coverage On Keros Therapeutics with Overweight Rating, Announces Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth has initiated coverage on Keros Therapeutics with an Overweight rating and set a price target of $60. The Overweight rating suggests that the analyst believes KROS has a higher potential to outperform the average total return of the stocks in the analyst's coverage universe.
December 08, 2023 | 6:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics has been given an Overweight rating by Wells Fargo with a price target of $60, indicating a positive outlook from the analyst.
The initiation of coverage by a major financial institution like Wells Fargo with an Overweight rating and a high price target is a strong positive signal for Keros Therapeutics. It suggests confidence in the company's future performance and may lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100